Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use

US12275791B2 · kind B2 · utility

Assignee

• Dragonfly Therapeutics, Inc. · US

Inventors

• Gregory P. Chang · Medford, US
• Ann F. Cheung · Lincoln, US
• Daniel Fallon · Winchester, US
• Asya Grinberg · Lexington, US
• William Haney · Wayland, US
• Steven O'Neil · Wayland, US
• Nicolai Wagtmann · Concord, US
• Ronnie Wei · Weston, US
• Bradley M. Lunde · Lebanon, US
• Bianka Prinz · Lebanon, US

Key dates

• Filing date: Aug 7, 2019
• Grant date: Apr 15, 2025
• Expiry date: Jul 17, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.